Karyopharm Therapeutics (KPTI) Debt Ratio (2024 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Debt Ratio came in at 1.07 in Q4 2025, up 85.64% YoY from 0.58 in Q4 2024, and up 6.63% on a QoQ basis from 1.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Debt Ratio (2024 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 2 years of Debt Ratio data on file, last reported at 1.07 in Q4 2025.
- Quarterly Debt Ratio rose 85.64% year-over-year to 1.07 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.07 (up 85.64% YoY) and the FY2025 annual result came in at 1.07, up 85.64% from the prior year.
- Debt Ratio improved to 1.07 in Q4 2025, from 1.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 1.07 in Q4 2025 to a low of 0.44 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.26 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.47 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.03 |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 1.13 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 |
| Dec 31, 2025 | 1.07 |
| Sep 30, 2025 | 1.00 |
| Jun 30, 2025 | 0.91 |
| Mar 31, 2025 | 0.75 |
| Dec 31, 2024 | 0.58 |
| Sep 30, 2024 | 0.50 |
| Jun 30, 2024 | 0.44 |